KARACHI: Dow University’s research lab has claimed that its experimental medicine appears to be almost 90 percent effective in preventing COVID-19.
Talking to M.M News, Research Team’s Head Dr. Shaukat Ali has informed that Pakistani scientists have achieved significant success in the fight against coronavirus pandemic. “Our experimental medicine has successfully treated 90 percent of the COVID-19 patients,” he added.
He further informed that the research team has prepared intravenous immunoglobulin (C-IVIG) from antibodies obtained from recovered patients of coronavirus. “The treatment is safe and has been approved by the US Food and Drug Administration,” he added.
In this method, immunoglobulin is prepared after the separation of antibodies found in the blood of a recovered patient from coronavirus. “The patients are kept in quarantine for 15 days after recovery,” he informed.
Dr. Shaukat added that the recovery rate among the COVID-19 patients included in the clinical trial was 100 percent, while the recovery rate among critically ill patients admitted to the Intensive Care Unit (ICU) is more than 60 percent.
He also informed that the Drug Regulatory Authority of Pakistan (DRAP) had approved clinical trials of C-IVIG in April and the primary funding for the project was provided by Dow University in collaboration with the Higher Education Commission.
